Company Filing History:
Years Active: 1993-1995
Title: Toshio Seto: Innovator in Antithrombotic and Antitumor Technologies
Introduction
Toshio Seto is a prominent inventor based in Ibaraki, Japan. He has made significant contributions to the fields of biotechnology and medicine, particularly in the development of novel therapeutic agents. With a total of 3 patents to his name, Seto's work focuses on enhancing antithrombotic and antitumor treatments.
Latest Patents
One of Seto's latest patents is for a human antithrombin III mutant. This innovative mutant exhibits high antithrombin activity without the need for heparin, making it effective in treating thrombotic disorders as an anticoagulant. The mutant is created by mutating specific amino acids at the reactive site and the heparin binding site of human antithrombin III using recombinant DNA technology. Additionally, the invention includes a method for mass-producing this mutant by incubating a host transformed with an expression vector containing the cDNA of the mutant.
Another significant patent involves a recombinant natural killer cell activator. This invention provides a cDNA coding for a recombinant natural killer cell activating factor, along with an expression plasmid and a transformed host. The antitumor agent derived from this factor is designed to contain a pharmacologically effective amount of the activating factor combined with a suitable carrier.
Career Highlights
Toshio Seto is currently associated with Eisai Company, Limited, where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions for complex medical challenges.
Collaborations
Seto has collaborated with notable colleagues, including Kentaro Yoshimatsu and Yukio Ohya, to further enhance the impact of his inventions.
Conclusion
Toshio Seto's contributions to biotechnology and medicine exemplify the spirit of innovation. His patents not only advance scientific knowledge but also hold the potential to improve patient outcomes in thrombotic and oncological treatments.